Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout
US Expansion Also Part Of Strategy
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
You may also be interested in...
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
Biopharma executives and investors descended on San Francisco again, but the numbers seemed fewer, the weather was volatile and the outlook for the sector remained uncertain.